Market Access News | pharmaphorum

News

CHMP backs Almirall’s eczema therapy lebrikizumab

Almirall is within sniffing distance of EU approval for its IL-13 inhibitor lebrikizumab for atopic dermatitis, setting up a challenge to Sanofi and Regeneron’s market-lea

News

GSK gets wide FDA approval for myelofibrosis drug

GSK's cancer unit has been given a fillip by the FDA with a broader-than-expected approval for JAK inhibitor momelotinib for anaemia associated with myelofibrosis, acquire

News

FDA capacity forces delay to Iovance's cell therapy

Iovance Biotherapeutics is facing a three-month delay in the review of its lifileucel cell therapy for melanoma in the US, held up by "insufficient resources" at the FDA.

News

FTC fires shot across pharma's bows over 'improper' patents

The financial regulator in the US has warned the pharma industry that it may consider legal action against companies that improperly list patents in the FDA's 'Orange Book

News

Alnylam's Onpattro clears FDA vote for ATTR-cardiomyopathy

Despite a sceptical appraisal by FDA reviewers, Alnylam's Onpattro has been recommended for approval as a treatment for transthyretin amyloidosis cardiomyopathy (ATTR-CM)

News

Vydura is first NICE-backed oral GPCR for acute migraine

Pfizer's Vydura has become the first drug in the oral GPCR receptor antagonist class to be recommended for routine NHS use as a treatment for acute migraine.

CHMP backs Almirall’s eczema therapy lebrikizumab

GSK gets wide FDA approval for myelofibrosis drug

FDA capacity forces delay to Iovance's cell therapy

FTC fires shot across pharma's bows over 'improper' patents

Alnylam's Onpattro clears FDA vote for ATTR-cardiomyopathy

Vydura is first NICE-backed oral GPCR for acute migraine

Severino takes the helm at Sarepta after turbulent spell

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks